

ASX Announcement

IMUGENE ANNOUNCES PUBLICATION OF PD1-VAXX ABSTRACT AT ASCO 2022

SYDNEY, Australia, 27 May 2022: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce results from its Phase 1 PD1-Vaxx IMPRINTER trial in adults with non-small cell lung cancer has been published today in an abstract at the American Society of Clinical Oncology's (ASCO) 2022 Annual Meeting.

The abstract is titled "IMPRINTER: An open label, multicenter, dose escalation/expansion, phase 1 study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer (IMU.201.101)".

The lead author is Professor Gary Richardson OAM, Director of the Cabrini Institute Research & Education, the Szalmuk Family Department of Medical Oncology and Oncology Clinics Victoria.

The abstract can be viewed at <https://meetings.asco.org/abstracts-presentations/212919>

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
investor@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia